RxDoctor Payments Data

Amit Gangoli, MD

Infectious Disease · Limerick, PANPI 1396732996

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $90,615 of the $122,502 with a category attached, or 74.0%. Paratek Pharmaceuticals, Inc. accounts for 60.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $48,097 and has fallen 99.9% since, to $28 in 2025. Among infectious disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$122,502in general payments, 2019–2025

Across 301 payments — averaging $406.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Paratek Pharmaceuticals, Inc.$74K
  • Melinta Therapeutics, LLC$27K
  • AbbVie$16K
  • Hikma Pharmaceuticals USA$3K
  • Viiv Healthcare Company$387
  • Johnson & Johnson$328
  • plus $1K from 7 others

What the payments were for

  • Consulting fees$1,5301%
  • Speaking & faculty fees$90,61574%
  • Travel & lodging$22,48318%
  • Food & beverage$7,8096%
  • Education$650%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$122,502 in reported general payments places this provider in the 95th percentile of 457 infectious disease providers in Pennsylvania.

See all infectious disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$131,049
Medicare patients
852
Services billed
1,281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen53$235,732
BiktarvyBictegrav/Emtricit/Tenofov Ala21$88,605
CompleraEmtricita/Rilpivirine/Tenof Df13$46,349
TriumeqAbacavir/Dolutegravir/Lamivudi12$44,214
DovatoDolutegravir Sodium/Lamivudine12$35,150
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df14$8,524
Daptomycin14$5,698
Vancomycin Hcl37$5,503
Cefepime Hcl13$2,290
Cephalexin62$1,212
Cefazolin Sodium26$326
Doxycycline Hyclate14$206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya, Biktarvy$273$324,33774 claims
Viiv Healthcare CompanyTriumeq, Dovato$387$79,36424 claims
Johnson & JohnsonComplera$328$46,34913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 457 infectious disease providers in Pennsylvania.

Other infectious disease in Limerick

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →